Ito Akihiko, Okada Morihito, Uchino Kazuya, Wakayama Tomohiko, Koma Yu-Ichiro, Iseki Shoichi, Tsubota Noriaki, Okita Yutaka, Kitamura Yukihiko
Department of Pathology, Osaka University Medical School, Suita, Osaka, Japan.
Lab Invest. 2003 Aug;83(8):1175-83. doi: 10.1097/01.lab.0000081391.28136.80.
TSLC1 (tumor suppressor in lung cancer-1) is an adhesion molecule of the Ig superfamily that binds homophilically and mediates cell-cell interactions. Originally, TSLC1 was cloned as a candidate tumor suppressor from the genomic region that frequently exhibits loss of heterogeneity in human non-small-cell lung cancer (NSCLC). However, there have been no studies on TSLC1 expression in normal lungs or NSCLC. Here we show that pulmonary epithelial cells express TSLC1 and its expression levels are often decreased or lost in primary pulmonary adenocarcinoma, a major histologic type of NSCLC. Immunohistochemistry revealed that TSLC1 was localized at cell-cell boundaries of all columnar epithelial cells in mouse embryonic lungs of 10.5 and 13 days postcoitus. Similar staining patterns were observed in bronchiolar and alveolar epithelial cells of adult human lungs, suggesting a physiologic role for TSLC1 in interactions of these cells. Next we performed Western blot analyses of TSLC1 in 47 primary pulmonary adenocarcinomas and judged each tumor as either decreased or nondecreased by comparing TSLC1 expression levels of the tumor with the levels of normal lungs. The expression profiles had a significant relation to histologic subtypes but not to other clinicopathologic parameters. Sixteen bronchioloalveolar carcinomas (BACs) were all judged nondecreased, while 19 of 31 (63%) adenocarcinomas other than BAC were judged decreased (p < 0.0001). Immunohistochemistry of tumors judged nondecreased revealed that not only BAC cells but also tumor cells in lepidic growth components of adenocarcinomas other than BAC expressed TSLC1 on their lateral plasma membranes. These tumor cells are considered less invasive because they proliferate in a lepidic growth pattern along alveolar walls. Thus, the present results not only support the hypothesis that TSLC1 is a tumor suppressor of NSCLC but also suggest that preserved integrity of TSLC1 may contribute to less invasive phenotypes of lepidic growth tumor cells.
TSLC1(肺癌-1肿瘤抑制因子)是免疫球蛋白超家族的一种黏附分子,可进行同源性结合并介导细胞间相互作用。最初,TSLC1是作为候选肿瘤抑制因子从人类非小细胞肺癌(NSCLC)中经常出现杂合性缺失的基因组区域克隆而来。然而,此前尚无关于TSLC1在正常肺组织或NSCLC中表达情况的研究。在此我们发现,肺上皮细胞表达TSLC1,而在原发性肺腺癌(NSCLC的主要组织学类型)中其表达水平常常降低或缺失。免疫组织化学显示,TSLC1定位于交配后10.5天和13天的小鼠胚胎肺中所有柱状上皮细胞的细胞间边界处。在成人肺的细支气管和肺泡上皮细胞中也观察到了类似的染色模式,这表明TSLC1在这些细胞的相互作用中具有生理作用。接下来,我们对47例原发性肺腺癌中的TSLC1进行了蛋白质印迹分析,并通过比较肿瘤中TSLC1的表达水平与正常肺组织中的水平,将每个肿瘤判断为表达降低或未降低。表达谱与组织学亚型有显著关系,但与其他临床病理参数无关。16例细支气管肺泡癌(BAC)均被判断为表达未降低,而31例非BAC腺癌中有19例(63%)被判断为表达降低(p < 0.0001)。对判断为表达未降低的肿瘤进行免疫组织化学分析发现,不仅BAC细胞,而且非BAC腺癌的鳞屑样生长成分中的肿瘤细胞在其外侧质膜上也表达TSLC1。这些肿瘤细胞被认为侵袭性较小,因为它们以鳞屑样生长模式沿肺泡壁增殖。因此,目前的结果不仅支持TSLC1是NSCLC肿瘤抑制因子的假说,还表明TSLC1的完整性得以保留可能有助于鳞屑样生长肿瘤细胞的侵袭性较小的表型。